Division of Allergan PLC
Latest From Actavis Group
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.
CREATES Act and 180-day exclusivity reforms also in legislation headed to US House floor, even as generic industry remains opposed to two of the three main provisions. The Rx pricing language is bundled with Obamacare language designed to force a tough vote by Republicans.
With $800m in upfront cash from United Therapeutics and $400m pegged to approvals for ralinepag, Arena gets capital for its R&D ambitions and a partner of choice to advance its Phase III PAH compound.
Having previously criticized the biopharma industry for squandering the benefits of US tax reform, the former Teva CEO called for more M&A deals that offer a clear strategic rationale, pointing to Takeda/Shire as an example.
- Generic Drugs
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Allergan PLC
- Senior Management
Claudio Albrecht, Chmn. & CEO
Mark Keatley, EVP, Fin.
Stefan J Sveinsson, EVP, R&D
Wolter Kuizinga, EVP, Bus. Dev.
- Contact Info
Phone: (354) 462 7300
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.